Association of Research and Development Investments With Treatment Costs for New Drugs Approved From 2009 to 2018.

ABSTRACT:

Importance

Drug companies frequently claim that high prices are needed to recoup spending on research and development. If high research and development costs justified high drug prices, then an association between these 2 measures would be expected.

Objective

To examine the association between treatment costs and research and development investments for new therapeutic agents approved by the US Food and Drug Administration (FDA) from 2009 to 2018.

Design, setting, and participants

This cross-sectional study analyzed 60 drugs approved by the FDA between January 1, 2009, and December 31, 2018, for which data on research and development investments and list or net prices were available. Data sources included the FDA and SSR Health databases.

Main outcomes and measures

SUBMITTER: Wouters OJ 

PROVIDER: S-EPMC9513642 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature